Authors

The Development of T-VEC for Melanoma

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.

Oncogenic TSHR Mutation in Papillary Thyroid Cancer

We present a case of a 49-year-old woman with a pT4aN1B papillary thyroid cancer who underwent radical thyroidectomy with bilateral neck dissection and RAI I-131 ablation, but poorly tolerated TSH suppression therapy due to tachycardia. Rising thyroglobulin levels and lymph node mapping showed recurrent/progressive disease in the thyroid bed.

The Impact of CTCs on Survival in Cervical Cancer

Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.

Sacituzumab Govitecan Safety: Manageable AEs in First-Line TNBC Therapy

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.

Smart Stop Trial: Targeted Therapy Cuts Chemo in LBCL

A targeted therapy-first approach shows promise in reducing chemotherapy needs for newly diagnosed large B-cell lymphoma patients, maintaining high response rates.

Radiosurgery Versus Radiotherapy Followed by Whole Brain Radiation for Brain Metastases

Kurt Jaeckle, MD, professor of neurology and oncology, Mayo Clinic, discusses radiosurgery versus radiotherapy followed by whole brain radiation for brain metastases.

Bundled Payment: Practice Savior or Killer?

Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.

Targeted Treatments Emerge for HER2 Mutations in Lung Cancer

HER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non–small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.

Reardon on ReACT: First Immunotherapy to Show Benefit in Glioblastoma

Targeted Oncology spoke with David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president of the Society for Neuro-Oncology, and lead author on the ReACT trial to better understand the significance of the study results for patients with glioblastoma.

Expert Discusses Quizartinib Promise in AML

The investigational tyrosine kinase inhibitor quizartinib is extremely promising as a monotherapy for patients with <em>FLT3-ITD&ndash;</em>positive relapsed acute myeloid leukemia.

Longer Letrozole Treatment Shows Limited Benefit in Early Breast Cancer

Extending treatment with letrozole by an additional 5 years after 5 years of successful treatment did not improve disease-free survival or overall survival in postmenopausal women with early-stage hormone receptor -positive breast cancer.

Web-Based Tool for Symptom Reporting Leads to Longer Survival in Advanced Cancer Patients

Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring.

Improving Surveillance for Hepatocellular Carcinoma

Controversy over optimal surveillance methods for hepatocellular carcinoma (HCC) continues to drive ongoing investigation into improved biomarkers and imaging techniques.

Body Composition and Targeted Therapies in Thyroid Cancer

Lily Kwatampora, MD, discusses the relationship between body composition and targeted therapies in patients with thyroid cancer.

US-Cuban Partnership Developing Anticancer Vaccine for NSCLC

Leaders of Roswell Park Cancer Institute (RPCI) in Buffalo, New York, have agreed to collaborate with the Center for Molecular Immunology (CIM) in Cuba to evaluate a therapeutic anticancer vaccine for non–small cell lung cancer (NSCLC) in the United States.

Riding the Wave of Chemoimmunotherapy: A New Era in Endometrial Cancer Management